Attention! Information is for reference only!
Before taking the course, consult a doctor!
WEB SITE ONLY DIRECTORY. NOT PHARMACY! We do not sell medicines! None!

Description of the medicine: Streptodeacas for injection (Streptodecasum pro injectionibus)

Streptodecase for injection (Streptodecasum pro injectionibus).

The drug streptokinase, belonging to the group of "immobilized" enzymes.

Has a prolonged fibrinolytic effect.

Powder or porous mass (in the form of a flat cake) white or white with a yellowish tinge. Easily soluble in water and isotonic sodium chloride solution.

The drug is based on the immobilization of streptokinase on a water-soluble matrix of a polysaccharide nature and is capable of prolonged active existence in the circulatory system. A single administration of an average therapeutic dose provides an increase in fibrinolytic activity of the blood within 48-72 hours.

The activity of the drug is expressed in fibrinolytic units (FE).

According to the effect on the body and indications for use, the drug is similar to other streptokinase preparations (see Streptoliasis).

Streptokinase is used to treat acute peripheral arterial thrombosis or thromboembolism (except in cases where emergency surgery is indicated), peripheral phlebothrombosis; Acute thromboembolism in the pulmonary artery system or in cases of recurrent thrombosis of small branches; Acute myocardial infarction on days 1 - 2 of the disease or recurrent course of the disease; Retrombosis after thrombectomy.

There are data on the use of streptodecase in ischemic stroke.

In ophthalmic practice streptodekazu is used for thrombosis of the central artery and vein of the eye.

Streptokinase intravenously is injected normally at an initial dose of 300,000 FE (trial dose), then an hour later, in the absence of side effects, an additional 2 700 000 FE (total dose 3 000 000 FE) are added additionally at a rate of 300 000 - 600 000 FE per minute.

In these doses, the drug causes a significant and prolonged increase in fibrinolytic activity of the blood, an increase in the content of the plasminogen activator and plasmin, has a pronounced therapeutic effect.

Streptodecase in therapeutic doses has little effect on blood coagulation.

To prevent rethrombosis, combined therapy with streptodecase and heparin is appropriate. Starting from the end of 1 day after the administration of a therapeutic dose of streptodeacase (3 000 000 FE), heparin is administered at a rate of 40,000 units per day (10,000 units every 6 hours) for 7 to 10 days.

Repeated injection of streptodekaza is permissible not earlier than 3 months after treatment in this scheme and only after the study of the titer of streptococcal antibodies. If necessary, repeated administration is usually performed at 6 months.

For the treatment of venous thrombosis of the retina of the eye, it is suggested to inject streptodekazu retrobulbarno 30 000 - 50 000 FE in 0.2 - 0.3 ml isotonic sodium chloride solution at intervals of 5 days. In the intervals between the injections, retrobulbarno is injected with heparin and dexamethasone.